[
    [
        {
            "time": "2019-06-01",
            "original_text": "新时代的猜想||医药行业2019年6月份投资月报【兴证医药】",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资月报",
                    "兴证医药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "新时代的猜想||医药行业2019年6月份投资月报【兴证医药】",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-06-03",
            "original_text": "平安证券：医药行业防御性战略配置价值突出",
            "features": {
                "keywords": [
                    "平安证券",
                    "医药行业",
                    "防御性",
                    "战略配置"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "平安证券：医药行业防御性战略配置价值突出",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-06-03",
            "original_text": "北向资金重现大幅回流:6月首个交易日净流入超44亿元",
            "features": {
                "keywords": [
                    "北向资金",
                    "大幅回流",
                    "净流入"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北向资金重现大幅回流:6月首个交易日净流入超44亿元",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-06-05",
            "original_text": "恒瑞医药：猛虎再添翼，10年抗PD-1布局终迎来收获期",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "PD-1",
                    "布局",
                    "收获期"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：猛虎再添翼，10年抗PD-1布局终迎来收获期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-07",
            "original_text": "医药界最牛夫妻档：翰森制药将敲锣收获千亿港元市值",
            "features": {
                "keywords": [
                    "翰森制药",
                    "市值",
                    "医药界"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药界最牛夫妻档：翰森制药将敲锣收获千亿港元市值",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-03",
            "original_text": "北上资金今天净流入44亿元 贵州茅台获净买入3.83亿元",
            "features": {
                "keywords": [
                    "北上资金",
                    "净流入",
                    "贵州茅台"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北上资金今天净流入44亿元 贵州茅台获净买入3.83亿元",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-06-03",
            "original_text": "北向资金6月首个交易日净流入超45亿元，机构：转机在6月",
            "features": {
                "keywords": [
                    "北向资金",
                    "净流入",
                    "机构",
                    "转机"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北向资金6月首个交易日净流入超45亿元，机构：转机在6月",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-06-10",
            "original_text": "精神疾病类制药公司翰森制药即将在港交所上市",
            "features": {
                "keywords": [
                    "翰森制药",
                    "上市",
                    "精神疾病"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "精神疾病类制药公司翰森制药即将在港交所上市",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-12",
            "original_text": "遭遇政策围城的德展健康：加码工业大麻能否解困？",
            "features": {
                "keywords": [
                    "德展健康",
                    "政策围城",
                    "工业大麻"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "遭遇政策围城的德展健康：加码工业大麻能否解困？",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-06-15",
            "original_text": "【西南医药】恒瑞医药（600276）：超级重磅PD-1单抗获批，成长最强动力就位",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "PD-1",
                    "单抗",
                    "获批"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【西南医药】恒瑞医药（600276）：超级重磅PD-1单抗获批，成长最强动力就位",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]